



California State Board of Pharmacy
1625 N. Market Blvd, Suite N 219, Sacramento, CA 95834
Phone (916) 574-7900
Fax (916) 574-8618
www.pharmacy.ca.gov

STATE AND CONSUMERS AFFAIRS AGENCY
DEPARTMENT OF CONSUMER AFFAIRS
ARNOLD SCHWARZENEGGER, GOVERNOR

To: Legislation and Regulation Committee

From: Staff

Subject: Board Sponsored Legislation

SB 1307 (Ridley-Thomas) Electronic Pedigree

The bill contains additional provisions to improve implementation issues involving serialization and electronic pedigrees. Specifically, it specifies that the serialization number must be contained in the electronic pedigree, staggers the implementation dates for e-pedigree compliance, allows for the grandfathering in of existing drug stock in the supply chain, and allows the board to establish criteria for interference requirements by regulation.

A copy of the language in its current form is found in **ATTACHMENT (B1a)**.

Omnibus Provisions

The following language was approved by the board to be included in an omnibus bill. Several of these provisions are currently included in SB 1779.

Use of Mobile Pharmacies

- (b1) Section 4062 Furnishing Dangerous Drugs During an Emergency
This section allows for the use of a mobile pharmacy in the event of a declared natural disaster if certain criteria are met.
- (b2) Section 4110 License Required, Temporary Permit Upon Transfer of Ownership
This section allows for the use of a mobile pharmacy on a temporary basis when a pharmacy is destroyed or damaged.

Pharmacist-in-Charge and Designated Representative in Charge

- (b3) Amend Sections 4022.5, 4101, 4101, 4160, 4196, 4305, 4329, 4330 and Add section 4036.5.
The Board of Pharmacy is proposing changes to several sections of Business and Professions Code, clarifying the reporting requirements for documenting a change in the Pharmacist-In-Charge (PIC). The PIC is responsible for the overall operations in a pharmacy. There are also similar changes for the Designated Representative-in-Charge (DRC) of a wholesaler or veterinary food-animal drug retailer. This proposal would also define the term "pharmacist-in-charge" currently referenced throughout pharmacy law as well as place into statute the approval process currently used by the board when evaluating a pharmacy application for approval of a proposed PIC or DRC.

General Omnibus Provisions

- (b4) Amend Section 4059.5 - Who May order Dangerous Drugs or Devices, Exceptions.
A technical change to this section clarifies that a designated representative must sign for and receive delivery of drugs by a wholesaler. This is important for accountability for drug purchases and receipt in wholesale operations.
- (b5) Section 4081 - Records of Dangerous Drugs and Devices Kept Open for Inspection; Maintenance of Records, Current Inventory
This section corrects a drafting error that occurred in Senate Bill 1307 (Chapter 857, statutes of 2004). The term "exemptee-in-charge" was incorrectly updated to "representative-in-charge" and requires correction to the appropriate term "designated representative in charge."
- (b6) Amend Section 4126.5 – Furnishing Dangerous Drugs by Pharmacy
This section clarifies specifically who in the supply chain may receive dangerous drugs furnished by a pharmacy.
- (b7) Amend Section 4231 – Requirements for Renewal of Pharmacist License: Clock Hours; Exemption for New Licensee
This section addresses the need to authorize the board to automatically inactivate a pharmacist license when a pharmacist, who certifies completion of the required CE as part of a renewal, fails to provide proof either as part of an audit or investigation. This authority already exists when a pharmacist fails to certify completion of continuing education as part of the renewal application.
- (b8) Section 4362 – Entry Into Pharmacists Recovery Program (PRP)
This section specifies the administrative co-pay participants pay as part of their participation in the PRP. The board subsidizes the administrative cost, however it requires the participant to also pay a portion of the administrative costs of the program. The current administrative co-pay, \$75.00, is set by contract only. The board has not sought a change in this co-pay in over 10 years, and has continually absorbed the additional monthly administrative fee, currently about \$230/month per participant.
- This section allows the board the ability to waive a participant's co-pay for demonstrated financial hardship.
- (b9) H&SC 11165 – Controlled Substance Utilization Review and Evaluation System: Establishment; Operation; Funding; Reporting to Legislature
This section requires an amendment requiring that a clinic that dispenses schedule III and schedule IV controlled substances must report weekly to CURES, similar to the requirements for pharmacies and prescribers who dispense controlled drugs as specified.

Corrections to Sections Referencing Prior Business and Professions Code §§ 4052

Omnibus changes based on recodification of Business and Professions Code section 4052

In 2006 Business and Professions Code section 4052 was recodified into four sections. The below B&PC and H&SC sections reference 4052 and require update.

- Section 733 – Dispensing Prescription Drugs and Devices
- Section 4027 – Skilled Nursing Facility – Intermediate Care Facility – Other Health Care Facilities
- Section 4040 – Prescription; Content Requirements

- Section 4051 – Conduct Limited to Pharmacist; Conduct Authorized by Pharmacist
- Section 4060 – Controlled Substance – Prescription Required, Exceptions
- Section 4076 – Prescription Container – Requirements for Labeling
- Section 4111 – Restrictions on Prescriber Ownership
- Section 4174 – Dispensing by Pharmacist Upon Order of Nurse Practitioner
- H&SC 11150 – Persons Authorized to Write or Issue a Prescription

A copy of the proposed language as presented to Senate Business and Professions is provided in **ATTACHMENT (B1b)**.

Immunizations by Pharmacists Pursuant to Published Recommendation of the Advisory Committee on Immunization Practices.

After consideration it was decided not to move this proposal this year. However, this proposal will be reconsidered for possible sponsorship in 2009.

Attachment – Agenda Item B1a

SB 1307 (Ridley-Thomas) Electronic
Pedigree

AMENDED IN SENATE MARCH 25, 2008

SENATE BILL

No. 1307

Introduced by Senator Ridley-Thomas

February 20, 2008

An act to amend ~~Section 4034~~ of Sections 4034, 4163, and 4163.5 of, and to add Sections 4163.2 and 4163.3 to, the Business and Professions Code, relating to pharmacy.

LEGISLATIVE COUNSEL'S DIGEST

SB 1307, as amended, Ridley-Thomas. Pharmacy: pedigree.

Existing law, the Pharmacy Law, provides for the licensure and regulation of the practice of pharmacy and the sale of dangerous drugs or dangerous devices by the California State Board of Pharmacy, in the Department of Consumer Affairs. Under existing law, on and after January 1, 2009, pedigree means an electronic record containing information regarding each transaction resulting in a change of ownership of a given dangerous drug, from sale by a manufacturer, through acquisition and sale by one or more wholesalers, manufacturers, or pharmacies, until final sale to a pharmacy or other person furnishing, administering, or dispensing the dangerous drug. On and after January 1, 2009, existing law prohibits a wholesaler or pharmacy from selling, trading, or transferring a dangerous drug without a pedigree ~~and prohibits a wholesaler or pharmacy~~ or from acquiring a dangerous drug without receiving a pedigree. Existing law, on and after January 1, 2009, requires that a pedigree include certain information, including, but not limited to, the source of the dangerous drug and the trade or generic name of the drug. Existing law authorizes the board to extend the January 1, 2009 compliance date to January 1, 2011, in specified

circumstances. Existing law makes it a crime to knowingly violate the Pharmacy Law.

This bill would *instead, on and after January 1, 2011, define a pedigree and would* require a pedigree to also include a specified unique identification number. By changing the definition of a crime, the bill would impose a state-mandated local program.

The bill would instead prohibit a wholesaler, on and after January 1, 2012, or a pharmacy, on and after July 1, 2012, from selling, trading, or transferring a dangerous drug without a pedigree or from acquiring a dangerous drug without receiving a pedigree. The bill would authorize the board to extend these compliance dates by up to one year if certain conditions are met.

The bill would authorize a manufacturer, wholesaler, or pharmacy in possession of dangerous drugs manufactured or distributed prior to the operative date of the pedigree requirements to designate these drugs as not subject to the requirements by preparing a specified written declaration under penalty of perjury. The bill would, for up to 18 months following the operative date of the pedigree requirements, authorize specified dangerous drugs to be purchased, sold, acquired, returned, or otherwise transferred, without meeting the pedigree requirements if the transfer complies with specified requirements, including a written declaration under penalty of perjury stating that the specified dangerous drug met certain requirements. Because the bill would expand the crime of perjury, the bill would impose a state-mandated local program.

The bill would require the board to promulgate regulations defining the circumstances where the board deems it appropriate for manufacturers, wholesalers, or pharmacies, to infer the contents of a case, pallet, or other aggregate of individual units, packages, or containers of dangerous drugs, from a unique identifier associated with the case, pallet, or other aggregate. The bill would declare the intent of the Legislature in this regard.

The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.

This bill would provide that no reimbursement is required by this act for a specified reason.

Vote: majority. Appropriation: no. Fiscal committee: yes.
State-mandated local program: yes.

The people of the State of California do enact as follows:

1 SECTION 1. Section 4034 of the Business and Professions
2 Code is amended to read:

3 4034. (a) "Pedigree" means a record, in electronic form,
4 containing information regarding each transaction resulting in a
5 change of ownership of a given dangerous drug, from sale by a
6 manufacturer, through acquisition and sale by one or more
7 wholesalers, manufacturers, or pharmacies, until final sale to a
8 pharmacy or other person furnishing, administering, or dispensing
9 the dangerous drug. The pedigree shall be created and maintained
10 in an interoperable electronic system, ensuring compatibility
11 throughout all stages of distribution.

12 (b) A pedigree shall include all of the following information:

13 (1) The source of the dangerous drug, including the name, the
14 federal manufacturer's registration number or a state license
15 number as determined by the board, and principal address of the
16 source.

17 (2) The trade or generic name of the drug, the quantity of the
18 dangerous drug, its dosage form and strength, the date of the
19 transaction, the sales invoice number, the container size, the
20 number of containers, the expiration dates, and the lot numbers.

21 (3) The business name, address, and the federal manufacturer's
22 registration number or a state license number as determined by the
23 board, of each owner of the dangerous drug, and the dangerous
24 drug shipping information, including the name and address of each
25 person certifying delivery or receipt of the dangerous drug.

26 (4) A certification under penalty of perjury from a responsible
27 party of the source of the dangerous drug that the information
28 contained in the pedigree is true and accurate.

29 (5) The unique identification number described in subdivision
30 (i).

31 (c) A single pedigree shall include every change of ownership
32 of a given dangerous drug from its initial manufacture through to
33 its final transaction to a pharmacy or other person for furnishing,
34 administering, or dispensing the drug, regardless of repackaging
35 or assignment of another National Drug Code (NDC) Directory
36 number.

37 (d) A pedigree shall track each dangerous drug at the smallest
38 package or immediate container distributed by the manufacturer,

1 received and distributed by the wholesaler, and received by the
2 pharmacy or another person furnishing, administering, or
3 dispensing the dangerous drug.

4 (e) Any return of a dangerous drug to a wholesaler or
5 manufacturer shall be documented on the same pedigree as the
6 transaction that resulted in the receipt of the drug by the party
7 returning it.

8 (f) If a licensed health care service plan, hospital organization,
9 and one or more physician organizations have exclusive contractual
10 relationships to provide health care services, drugs distributed
11 between these persons shall be deemed not to have changed
12 ownership.

13 (g) The following transactions are not required to be recorded
14 on a pedigree:

15 (1) The provision of samples of dangerous drugs by a
16 manufacturer's employee to an authorized prescriber, provided
17 the samples are dispensed to a patient of the prescriber without
18 charge.

19 (2) An injectable dangerous drug that is delivered by the
20 manufacturer directly to an authorized prescriber or other entity
21 directly responsible for administration of the injectable dangerous
22 drug, only for an injectable dangerous drug that by law may only
23 be administered under the professional supervision of the prescriber
24 or other entity directly responsible for administration of the drug.
25 Injectable dangerous drugs exempted from the pedigree
26 requirement by this paragraph may not be dispensed to a patient
27 or a patient's agent for self-administration, and shall only be
28 administered to the patient, as defined in Section 4016, by the
29 prescriber or other authorized entity that received the drug directly
30 from the manufacturer.

31 (3) The exemption in paragraph (2) shall expire and be
32 inoperative on January 1, ~~2010~~ 2012, unless prior to that date the
33 board receives, at a public hearing, evidence that entities involved
34 in the distribution of the injectable dangerous drugs subject to that
35 paragraph are not able to provide a pedigree in compliance with
36 all of the provisions of California law, and the board votes to
37 extend the expiration date for the exemption until January 1, ~~2011~~
38 2013. The decision as to whether to extend the expiration date
39 shall be within the sole discretion of the board, and shall not be

1 subject to the requirements of Chapter 3.5 (commencing with
2 Section 11340) of Part 1 of Division 3 of the Government Code.

3 (h) If a manufacturer, wholesaler, or pharmacy has reasonable
4 cause to believe that a dangerous drug in, or having been in, its
5 possession is counterfeit or the subject of a fraudulent transaction,
6 the manufacturer, wholesaler, or pharmacy shall notify the board
7 within 72 hours of obtaining that knowledge. This subdivision
8 shall apply to any dangerous drug that has been sold or distributed
9 in or through this state.

10 (i) “Interoperable electronic system” as used in this chapter
11 means an electronic track and trace system for dangerous drugs
12 that uses a unique identification number, established at the point
13 of manufacture, contained within a standardized nonproprietary
14 data format and architecture, that is uniformly used by
15 manufacturers, wholesalers, and pharmacies for the pedigree of a
16 dangerous drug.

17 (j) The application of the pedigree requirement in pharmacies
18 shall be subject to review during the board’s sunset review to be
19 conducted as described in subdivision (f) of Section 4001.

20 (k) This section shall become operative on January 1, ~~2009~~
21 ~~2011~~. However, the board may extend the date for compliance
22 with this section and Section 4163 ~~until January 1, 2011~~, in
23 accordance with Section 4163.5.

24 *SEC. 2. Section 4163 of the Business and Professions Code is*
25 *amended to read:*

26 4163. (a) A manufacturer or wholesaler may not furnish a
27 dangerous drug or dangerous device to an unauthorized person.

28 (b) Dangerous drugs or dangerous devices shall be acquired
29 from a person authorized by law to possess or furnish dangerous
30 drugs or dangerous devices. When the person acquiring the
31 dangerous drugs or dangerous devices is a wholesaler, the
32 obligation of the wholesaler shall be limited to obtaining
33 confirmation of licensure of those sources from whom it has not
34 previously acquired dangerous drugs or dangerous devices.

35 (c) Except as otherwise provided in Section 4163.5, commencing
36 on January 1, ~~2009~~ ~~2012~~, a wholesaler ~~or pharmacy~~ may not sell,
37 trade, or transfer a dangerous drug at wholesale without providing
38 a pedigree.

1 (d) Except as otherwise provided in Section 4163.5, commencing
2 on January 1, ~~2009~~ 2012, a wholesaler or pharmacy may not
3 acquire a dangerous drug without receiving a pedigree.

4 (e) *Except as otherwise provided in Section 4163.5, commencing*
5 *on July 1, 2012, a pharmacy may not sell, trade, or transfer a*
6 *dangerous drug at wholesale without providing a pedigree.*

7 (f) *Except as otherwise provided in Section 4163.5, commencing*
8 *on July 1, 2012, a pharmacy may not acquire a dangerous drug*
9 *without receiving a pedigree.*

10 SEC. 3. Section 4163.2 is added to the Business and Professions
11 Code, to read:

12 4163.2. (a) (1) *A manufacturer, wholesaler, or pharmacy*
13 *lawfully possessing or owning dangerous drugs manufactured or*
14 *distributed prior to the operative date of the pedigree requirements,*
15 *specified in Sections 4034 and 4163, may designate these*
16 *dangerous drugs as not subject to the pedigree requirements by*
17 *preparing a written declaration made under penalty of perjury*
18 *that lists those dangerous drugs.*

19 (2) *The written declaration shall include the unique*
20 *identification numbers and the dates of manufacture for each*
21 *dangerous drug designated. The written declaration shall be*
22 *submitted to and received by the board no later than 30 days after*
23 *the operative date of the pedigree requirements. The entity or*
24 *person submitting the written declaration shall also retain for a*
25 *period of three years and make available for inspection by the*
26 *board a copy of each written declaration submitted.*

27 (3) *The board may, by regulation, further specify the*
28 *requirements and procedures for the creation and submission of*
29 *these written declarations.*

30 (b) (1) *For up to 18 months following the operative date of the*
31 *pedigree requirements, any dangerous drugs designated on a*
32 *written declaration timely created and submitted to the board may*
33 *be purchased, sold, acquired, returned, or otherwise transferred*
34 *without meeting the pedigree requirements, if the transfer complies*
35 *with the other requirements of this chapter.*

36 (2) *Any transfer of a dangerous drug without meeting the*
37 *pedigree requirements shall be accompanied by a written*
38 *declaration made under penalty of perjury by a responsible party*
39 *of the transferring entity or person stating that the dangerous drug,*
40 *identified by its unique identification number and date of*

1 *manufacture, met the requirements of subdivision (a) and the*
2 *written declaration prepared pursuant to subdivision (a) shall be*
3 *attached to this written declaration.*

4 *(3) Both the transferring and receiving parties shall retain for*
5 *a period of three years and make available for inspection by the*
6 *board a copy of each written declaration.*

7 *(4) The board may, by regulation, further specify the*
8 *requirements and procedures for these transfers and the necessary*
9 *documentation.*

10 *(5) The board may, by regulation, further extend beyond 18*
11 *months the period for transfers of nonpedigreed drugs, either for*
12 *all drugs or for specified categories or subcategories of drugs.*

13 *SEC. 4. Section 4163.3 is added to the Business and Professions*
14 *Code, to read:*

15 *4163.3. (a) It is the intent of the Legislature that participants*
16 *in the distribution chain for dangerous drugs, including*
17 *manufacturers, wholesalers, or pharmacies furnishing,*
18 *administering, or dispensing dangerous drugs, distribute and*
19 *receive electronic pedigrees, and verify and validate the delivery*
20 *and receipt of dangerous drugs against those pedigrees at the unit*
21 *level, in a manner that maintains the integrity of the pedigree*
22 *system without an unacceptable increase in the risk of diversion*
23 *or counterfeiting.*

24 *(b) To meet this goal, the board shall, by regulation, define the*
25 *circumstances, if any, under which the board deems it appropriate*
26 *for participants in the distribution chain to infer the contents of a*
27 *case, pallet, or other aggregate of individual units, packages, or*
28 *containers of dangerous drugs, from a unique identifier associated*
29 *with the case, pallet, or other aggregate, without opening each*
30 *case, pallet, or other aggregate or otherwise individually validating*
31 *each unit.*

32 *SEC. 5. Section 4163.5 of the Business and Professions Code*
33 *is amended to read:*

34 *4163.5. The board may extend the date for compliance with*
35 *the requirement for a pedigree set forth in Sections 4034 and 4163*
36 *until January 1, 2011, if it determines subject to the following*
37 *conditions. If the board determines that manufacturers—~~or,~~*
38 *wholesalers, or pharmacies require additional time to implement*
39 *electronic technologies to track the distribution of dangerous drugs*
40 *within the state, the board may delay the operative date of Sections*

1 4034 and 4163 by up to one year for any or all of these participants
2 in the distribution chain, to any date up to January 1, 2012, for
3 manufacturers, to any date up to January 1, 2013, for wholesalers,
4 and to any date up to July 1, 2013, for pharmacies. A determination
5 by the board to extend the deadline for providing pedigrees shall
6 not be subject to the requirements of Chapter 3.5 (commencing
7 with Section 11340) of Part 1 of Division 3 of Title 2 of the
8 Government Code.

9 ~~SEC. 2.~~

10 *SEC. 6.* No reimbursement is required by this act pursuant to
11 Section 6 of Article XIII B of the California Constitution because
12 the only costs that may be incurred by a local agency or school
13 district will be incurred because this act creates a new crime or
14 infraction, eliminates a crime or infraction, or changes the penalty
15 for a crime or infraction, within the meaning of Section 17556 of
16 the Government Code, or changes the definition of a crime within
17 the meaning of Section 6 of Article XIII B of the California
18 Constitution.

Attachment – Agenda Item B1b

Omnibus Language

Proposed Omnibus Provisions for 2008

Business and Professions Code Amendments

§ 733. Dispensing Prescription Drugs and Devices

(a) No licentiate shall obstruct a patient in obtaining a prescription drug or device that has been legally prescribed or ordered for that patient. A violation of this section constitutes unprofessional conduct by the licentiate and shall subject the licentiate to disciplinary or administrative action by his or her licensing agency.

(b) Notwithstanding any other provision of law, a licentiate shall dispense drugs and devices, as described in subdivision (a) of Section 4024, pursuant to a lawful order or prescription unless one of the following circumstances exists:

(1) Based solely on the licentiate's professional training and judgment, dispensing pursuant to the order or the prescription is contrary to law, or the licentiate determines that the prescribed drug or device would cause a harmful drug interaction or would otherwise adversely affect the patient's medical condition.

(2) The prescription drug or device is not in stock. If an order, other than an order described in Section 4019, or prescription cannot be dispensed because the drug or device is not in stock, the licentiate shall take one of the following actions:

(A) Immediately notify the patient and arrange for the drug or device to be delivered to the site or directly to the patient in a timely manner.

(B) Promptly transfer the prescription to another pharmacy known to stock the prescription drug or device that is near enough to the site from which the prescription or order is transferred, to ensure the patient has timely access to the drug or device.

(C) Return the prescription to the patient and refer the patient. The licentiate shall make a reasonable effort to refer the patient to a pharmacy that stocks the prescription drug or device that is near enough to the referring site to ensure that the patient has timely access to the drug or device.

(3) The licentiate refuses on ethical, moral, or religious grounds to dispense a drug or device pursuant to an order or prescription. A licentiate may decline to dispense a prescription drug or device on this basis only if the licentiate has previously notified his or her employer, in writing, of the drug or class of drugs to which he or she objects, and the licentiate's employer can, without creating undue hardship, provide a reasonable accommodation of the licentiate's objection. The licentiate's employer shall establish protocols that ensure that the patient has timely access to the prescribed drug or device despite the licentiate's refusal to dispense the prescription or order. For purposes of this section, "reasonable accommodation" and "undue hardship" shall have the same meaning as applied to those terms pursuant to subdivision (I) of Section 12940 of the Government Code.

(c) For the purposes of this section, "prescription drug or device" has the same meaning as the definition in Section 4022.

(d) The provisions of this section shall apply to the drug therapy described in paragraph (8) of subdivision (a) of Section ~~4052~~ 4052.3.

(e) This section imposes no duty on a licentiate to dispense a drug or device pursuant to a prescription or order without payment for the drug or device, including payment directly by the patient or through a third party payer accepted by the licentiate or payment of any required copayment by the patient.

§ 4022.5. Designated representative; designated representative-in-charge

(a) "Designated representative" means an individual to whom a license has been granted pursuant to Section 4053. A pharmacist fulfilling the duties in Section 4053 shall not be required to obtain a license as a designated representative.

(b) "Designated representative-in-charge" means a designated representative or a pharmacist proposed by a wholesaler or veterinary food-animal drug retailer and approved by the board who is as the supervisor or manager of a responsible for ensuring the wholesaler's or veterinary food-animal drug retailer's compliance with all state and federal laws and regulations pertaining to practice in the applicable license category.

§ 4027. Skilled Nursing Facility – Intermediate Care Facility – Other Health Care Facilities

(a) As used in this chapter, the terms "skilled nursing facility," "intermediate care facility," and other references to health facilities shall be construed with respect to the definitions contained in Article 1 (commencing with Section 1250) of Chapter 2 of Division 2 of the Health and Safety Code.

(b) As used in paragraph (4) of subdivision (a) of Section ~~4052~~ 4052.1, "licensed health care facility" means a facility licensed pursuant to Article 1 (commencing with Section 1250) of Chapter 2 of Division 2 of the Health and Safety Code or a facility, as defined in Section 1250 of the Health and Safety Code, operated by a health care service plan licensed pursuant to Chapter 2.2 (commencing with Section 1340) of Division 2 of the Health and Safety Code.

(c) As used in paragraph (5) of subdivision (a) of Section ~~4052~~ 4052.2, "health care facility" means a facility, other than a facility licensed under Division 2 (commencing with Section 1200) of the Health and Safety Code, that is owned or operated by a health care service plan licensed pursuant to Chapter 2.2 (commencing with Section 1340) of the Health and Safety Code, or by an organization under common ownership or control of the health care service plan; "licensed home health agency" means a private or public organization licensed by the State Department of Health Services pursuant to Chapter 8 (commencing with Section 1725) of Division 2 of the Health and Safety Code, as further defined in Section 1727 of the Health and Safety Code; and "licensed clinic" means a clinic licensed pursuant to Article 1 (commencing with Section 1200) of Chapter 1 of Division 2 of the Health and Safety Code.

(d) "Licensed health care facility" or "facility," as used in Section 4065, means a health facility licensed pursuant to Article 1 (commencing with Section 1250) of Chapter 2 of Division 2 of the Health and Safety Code or a facility that is owned or operated by a health care service plan licensed pursuant to Chapter 2.2 (commencing with Section 1340) of Division 2 of the Health and Safety Code or by an organization under common ownership or control with the health care service plan.

§ 4036.5. Pharmacist-in-charge

"Pharmacist-in-charge" means a pharmacist proposed by a pharmacy and approved by the board as the supervisor or manager responsible for ensuring the pharmacy's compliance with all state and federal laws and regulations pertaining to the practice of pharmacy.

§ 4040. Prescription; Content Requirements

(a) "Prescription" means an oral, written, or electronic transmission order that is both of the following:

(1) Given individually for the person or persons for whom ordered that includes all of the following:

(A) The name or names and address of the patient or patients.

(B) The name and quantity of the drug or device prescribed and the directions for use.

(C) The date of issue.

(D) Either rubber stamped, typed, or printed by hand or typeset, the name, address, and telephone number of the prescriber, his or her license classification, and his or her federal registry number, if a controlled substance is prescribed.

(E) A legible, clear notice of the condition for which the drug is being prescribed, if requested by the patient or patients.

(F) If in writing, signed by the prescriber issuing the order, or the certified nurse-midwife, nurse practitioner, physician assistant, or naturopathic doctor who issues a drug order pursuant to Section 2746.51, 2836.1, 3502.1, or 3640.5, respectively, or the pharmacist who issues a drug order pursuant to either subparagraph (D) of paragraph (4) of, or clause (iv) of subparagraph (A) of paragraph (5) of, subdivision (a) of Section 4052 ~~4052.2~~.

(2) Issued by a physician, dentist, optometrist, podiatrist, veterinarian, or naturopathic doctor pursuant to Section 3640.7 or, if a drug order is issued pursuant to Section 2746.51, 2836.1, 3502.1, or 3460.5, by a certified nurse-midwife, nurse practitioner, physician assistant, or naturopathic doctor licensed in this state, or pursuant to either subparagraph (D) of paragraph (4) of, or clause (iv) of subparagraph (A) of paragraph (5) of, subdivision (a) of Section 4052 ~~4052.2~~ by a pharmacist licensed in this state.

(b) Notwithstanding subdivision (a), a written order of the prescriber for a dangerous drug, except for any Schedule II controlled substance, that contains at least the name and signature of the prescriber, the name and address of the patient in a manner consistent with paragraph (3) of subdivision (b) of Section 11164 of the Health and Safety Code, the name and quantity of the drug prescribed, directions for use, and the date of issue may be treated as a prescription by the dispensing pharmacist as long as any additional information required by subdivision (a) is readily retrievable in the pharmacy. In the event of a conflict between this subdivision and Section 11164 of the Health and Safety Code, Section 11164 of the Health and Safety Code shall prevail.

(c) "Electronic transmission prescription" includes both image and data prescriptions.

"Electronic image transmission prescription" means any prescription order for which a facsimile of the order is received by a pharmacy from a licensed prescriber. "Electronic data transmission prescription" means any prescription order, other than an electronic image transmission prescription, that is electronically transmitted from a licensed prescriber to a pharmacy.

(d) The use of commonly used abbreviations shall not invalidate an otherwise valid prescription.

(e) Nothing in the amendments made to this section (formerly Section 4036) at the 1969 Regular Session of the Legislature shall be construed as expanding or limiting the right that a chiropractor, while acting within the scope of his or her license, may have to prescribe a device.

§ 4051. Conduct Limited to Pharmacist; Conduct Authorized by Pharmacist

(a) Except as otherwise provided in this chapter, it is unlawful for any person to manufacture, compound, furnish, sell, or dispense any dangerous drug or dangerous device, or to dispense or compound any prescription pursuant to Section 4040 of a prescriber unless he or she is a pharmacist under this chapter.

(b) Notwithstanding any other law, a pharmacist may authorize the initiation of a prescription, pursuant to Section ~~4052~~ 4052.2, and otherwise provide clinical advice or information or patient consultation if all of the following conditions are met:

- (1) The clinical advice or information or patient consultation is provided to a health care professional or to a patient.
- (2) The pharmacist has access to prescription, patient profile, or other relevant medical information for purposes of patient and clinical consultation and advice.
- (3) Access to the information described in paragraph (2) is secure from unauthorized access and use.

§ 4059.5. Who may order dangerous drugs or devices, exceptions

(a) Except as otherwise provided in this chapter, dangerous drugs or dangerous devices may only be ordered by an entity licensed by the board and shall be delivered to the licensed premises and signed for and received by a pharmacist. Where a licensee is permitted to operate through a designated representative, ~~the~~ a designated representative ~~may~~ must sign for and receive the delivery.

(b) A dangerous drug or dangerous device transferred, sold, or delivered to a person within this state shall be transferred, sold, or delivered only to an entity licensed by the board, to a manufacturer, or to an ultimate user or the ultimate user's agent.

(c) Notwithstanding subdivisions (a) and (b), deliveries to a hospital pharmacy may be made to a central receiving location within the hospital. However, the dangerous drugs or dangerous devices shall be delivered to the licensed pharmacy premises within one working day following receipt by the hospital, and the pharmacist on duty at that time shall immediately inventory the dangerous drugs or dangerous devices.

(d) Notwithstanding any other provision of law, a dangerous drug or dangerous device may be ordered by and provided to a manufacturer, physician, dentist, podiatrist, optometrist, veterinarian, naturopathic doctor pursuant to Section 3640.7, or laboratory, or a physical therapist acting within the scope of his or her license. A person or entity receiving delivery of a dangerous drug or dangerous device, or a duly authorized representative of the person or entity, shall sign for the receipt of the dangerous drug or dangerous device.

(e) A dangerous drug or dangerous device shall not be transferred, sold, or delivered to a person outside this state, whether foreign or domestic, unless the transferor, seller, or deliverer does so in compliance with the laws of this state and of the United States and of the

state or country to which the dangerous drugs or dangerous devices are to be transferred, sold, or delivered. Compliance with the laws of this state and the United States and of the state or country to which the dangerous drugs or dangerous devices are to be delivered shall include, but not be limited to, determining that the recipient of the dangerous drugs or dangerous devices is authorized by law to receive the dangerous drugs or dangerous devices.

(f) Notwithstanding subdivision (a), a pharmacy may take delivery of dangerous drugs and dangerous devices when the pharmacy is closed and no pharmacist is on duty if all of the following requirements are met:

- (1) The drugs are placed in a secure storage facility in the same building as the pharmacy.
- (2) Only the pharmacist-in-charge or a pharmacist designated by the pharmacist-in-charge has access to the secure storage facility after dangerous drugs or dangerous devices have been delivered.
- (3) The secure storage facility has a means of indicating whether it has been entered after dangerous drugs or dangerous devices have been delivered.
- (4) The pharmacy maintains written policies and procedures for the delivery of dangerous drugs and dangerous devices to a secure storage facility.
- (5) The agent delivering dangerous drugs and dangerous devices pursuant to this subdivision leaves documents indicating the name and amount of each dangerous drug or dangerous device delivered in the secure storage facility.

The pharmacy shall be responsible for the dangerous drugs and dangerous devices delivered to the secure storage facility. The pharmacy shall also be responsible for obtaining and maintaining records relating to the delivery of dangerous drugs and dangerous devices to a secure storage facility.

(g) This section shall become operative on January 1, 2006.

§ 4060. Controlled Substance – Prescription Required, Exceptions

No person shall possess any controlled substance, except that furnished to a person upon the prescription of a physician, dentist, podiatrist, optometrist, veterinarian, or naturopathic doctor pursuant to Section 3640.7, or furnished pursuant to a drug order issued by a certified nurse-midwife pursuant to Section 2746.51, a nurse practitioner pursuant to Section 2836.1, a physician assistant pursuant to Section 3502.1, a naturopathic doctor pursuant to Section 3640.5, or a pharmacist pursuant to ~~either subparagraph (D) of paragraph (4) of, or clause (iv) of subparagraph (A) of paragraph (5) of, subdivision (a) of Section 4052~~ 4052.2. This section shall not apply to the possession of any controlled substance by a manufacturer, wholesaler, pharmacy, pharmacist, physician, podiatrist, dentist, optometrist, veterinarian, naturopathic doctor, certified nurse-midwife, nurse practitioner, or physician assistant, when in stock in containers correctly labeled with the name and address of the supplier or producer. Nothing in this section authorizes a certified nurse-midwife, a nurse practitioner, a physician assistant, or a naturopathic doctor, to order his or her own stock of dangerous drugs and devices.

§ 4062. Furnishing Dangerous Drugs During and Emergency

(a) Notwithstanding Section 4059 or any other provision of law, a pharmacist may, in good faith, furnish a dangerous drug or dangerous device in reasonable quantities without a prescription during a federal, state, or local emergency, to further the health and safety of the public. A record containing the date, name, and address of the person to whom the drug or

device is furnished, and the name, strength, and quantity of the drug or device furnished shall be maintained. The pharmacist shall communicate this information to the patient's attending physician as soon as possible. Notwithstanding Section 4060 or any other provision of law, a person may possess a dangerous drug or dangerous device furnished without prescription pursuant to this section.

(b) During a declared federal, state, or local emergency, the board may waive application of any provisions of this chapter or the regulations adopted pursuant to it if, in the board's opinion, the waiver will aid in the protection of public health or the provision of patient care.

(c) During a declared federal, state, or local emergency the board will allow for the deployment of a mobile pharmacy to impacted areas to ensure the continuity of patient care if all of the following conditions are met:

(1) The mobile pharmacy shares common ownership with at least one currently licensed pharmacy in good standing;

(2) The mobile pharmacy retains records of dispensing as required in subdivision (a);

(3) A licensed pharmacist is on the premises, and the mobile pharmacy is under the control and management of a pharmacist while the drugs are being dispensed;

(4) Reasonable security measures are taken to safeguard the drug supply maintained in the mobile pharmacy;

(5) The mobile pharmacy is located within the declared disaster area or affected areas; and

(6) The mobile pharmacy ceases the provisions of services within forty-eight (48) hours following the termination of the declared emergency.

§ 4076. Prescription Container – Requirements for Labeling

(a) A pharmacist shall not dispense any prescription except in a container that meets the requirements of state and federal law and is correctly labeled with all of the following:

(1) Except where the prescriber or the certified nurse-midwife who functions pursuant to a standardized procedure or protocol described in Section 2746.51, the nurse practitioner who functions pursuant to a standardized procedure described in Section 2836.1, or protocol, the physician assistant who functions pursuant to Section 3502.1, the naturopathic doctor who functions pursuant to a standardized procedure or protocol described in Section 3640.5, or the pharmacist who functions pursuant to a policy, procedure, or protocol pursuant to either subparagraph (D) of paragraph (4) of, or clause (iv) of subparagraph (A) of paragraph (5) of, subdivision (a) of Section 4052 ~~4052.2~~ orders otherwise, either the manufacturer's trade name of the drug or the generic name and the name of the manufacturer. Commonly used abbreviations may be used. Preparations containing two or more active ingredients may be identified by the manufacturer's trade name or the commonly used name or the principal active ingredients.

(2) The directions for the use of the drug.

(3) The name of the patient or patients.

(4) The name of the prescriber or, if applicable, the name of the certified nurse-midwife who functions pursuant to a standardized procedure or protocol described in Section 2746.51, the nurse practitioner who functions pursuant to a standardized procedure described in Section 2836.1, or protocol, the physician assistant who functions pursuant to Section 3502.1, the naturopathic doctor who functions pursuant to a standardized procedure or protocol described in Section 3640.5, or the pharmacist who functions pursuant to a policy, procedure, or protocol pursuant to either subparagraph (D) of paragraph (4) of, or clause (iv) of subparagraph (A) of paragraph (5) of, subdivision (a) of Section 4052.

(5) The date of issue.

- (6) The name and address of the pharmacy, and prescription number or other means of identifying the prescription.
- (7) The strength of the drug or drugs dispensed.
- (8) The quantity of the drug or drugs dispensed.
- (9) The expiration date of the effectiveness of the drug dispensed.
- (10) The condition for which the drug was prescribed if requested by the patient and the condition is indicated on the prescription.
- (11) (A) Commencing January 1, 2006, the physical description of the dispensed medication, including its color, shape, and any identification code that appears on the tablets or capsules, except as follows:
 - (i) Prescriptions dispensed by a veterinarian.
 - (ii) An exemption from the requirements of this paragraph shall be granted to a new drug for the first 120 days that the drug is on the market and for the 90 days during which the national reference file has no description on file.
 - (iii) Dispensed medications for which no physical description exists in any commercially available database.
- (B) This paragraph applies to outpatient pharmacies only.
- (C) The information required by this paragraph may be printed on an auxiliary label that is affixed to the prescription container.
- (D) This paragraph shall not become operative if the board, prior to January 1, 2006, adopts regulations that mandate the same labeling requirements set forth in this paragraph.

(b) If a pharmacist dispenses a prescribed drug by means of a unit dose medication system, as defined by administrative regulation, for a patient in a skilled nursing, intermediate care, or other health care facility, the requirements of this section will be satisfied if the unit dose medication system contains the aforementioned information or the information is otherwise readily available at the time of drug administration.

(c) If a pharmacist dispenses a dangerous drug or device in a facility licensed pursuant to Section 1250 of the Health and Safety Code, it is not necessary to include on individual unit dose containers for a specific patient, the name of the certified nurse-midwife who functions pursuant to a standardized procedure or protocol described in Section 2746.51, the nurse practitioner who functions pursuant to a standardized procedure described in Section 2836.1, or protocol, the physician assistant who functions pursuant to Section 3502.1, the naturopathic doctor who functions pursuant to a standardized procedure or protocol described in Section 3640.5, or the pharmacist who functions pursuant to a policy, procedure, or protocol pursuant to either subparagraph (D) of paragraph (4) of, or clause (iv) of subparagraph (A) of paragraph (5) of, subdivision (a) of Section 4052.

(d) If a pharmacist dispenses a prescription drug for use in a facility licensed pursuant to Section 1250 of the Health and Safety Code, it is not necessary to include the information required in paragraph (11) of subdivision (a) when the prescription drug is administered to a patient by a person licensed under the Medical Practice Act (Chapter 5 (commencing with Section 2000)), the Nursing Practice Act (Chapter 6 (commencing with Section 2700)), or the Vocational Nursing Practice Act (Chapter 6.5 (commencing with Section 2840)), who is acting within his or her scope of practice.

§ 4081. Records of Dangerous Drugs and Devices Kept Open for Inspection; Maintenance of Records, Current Inventory

(a) All records of manufacture and of sale, acquisition, or disposition of dangerous drugs or dangerous devices shall be at all times during business hours open to inspection by authorized

officers of the law, and shall be preserved for at least three years from the date of making. A current inventory shall be kept by every manufacturer, wholesaler, pharmacy, veterinary food-animal drug retailer, physician, dentist, podiatrist, veterinarian, laboratory, clinic, hospital, institution, or establishment holding a currently valid and unrevoked certificate, license, permit, registration, or exemption under Division 2 (commencing with Section 1200) of the Health and Safety Code or under Part 4 (commencing with Section 16000) of Division 9 of the Welfare and Institutions Code who maintains a stock of dangerous drugs or dangerous devices.

(b) The owner, officer, and partner of a pharmacy, wholesaler, or veterinary food-animal drug retailer shall be jointly responsible, with the pharmacist-in-charge or designated representative-in-charge, for maintaining the records and inventory described in this section.

(c) The pharmacist-in-charge or representative-in-charge shall not be criminally responsible for acts of the owner, officer, partner, or employee that violate this section and of which the pharmacist-in-charge or designated representative-in-charge had no knowledge, or in which he or she did not knowingly participate.

(d) This section shall become operative on January 1, 2006.

§ 4101. ~~Persons in charge of pharmacy or exemptees~~ Pharmacist-in-charge; designated-representative-in-charge; termination of employment status; duty to notify board

(a) A pharmacist who ~~takes~~ may take charge of, ~~or acts and act~~ as the pharmacist-in-charge of a pharmacy ~~or other entity licensed by the board upon application by the pharmacy and approval by the board.~~ Any pharmacist-in-charge who terminates his or her employment at the pharmacy ceases to act as the pharmacist-in-charge of the pharmacy or other entity, shall notify the board in writing within 30 days of the termination of employment date of such change in status.

(b) ~~An exemptee~~ A designated representative or a pharmacist may take charge of and act as the designated representative-in-charge of a wholesaler or veterinary food drug-animal retailer upon application by the wholesaler or veterinary food drug-animal retailer and approval by the board. ~~Any designated representative-in-charge who terminates his or her employment ceases to act as the designated representative-in-charge at that entity,~~ shall notify the board in writing within 30 days of the termination of employment date of such change in status.

§ 4110 License Required, Temporary Permit Upon Transfer of Ownership

(a) No person shall conduct a pharmacy in the State of California unless he or she has obtained a license from the board. A license shall be required for each pharmacy owned or operated by a specific person. A separate license shall be required for each of the premises of any person operating a pharmacy in more than one location. The license shall be renewed annually. The board may, by regulation, determine the circumstances under which a license may be transferred.

(b) The board may, at its discretion, issue a temporary permit, when the ownership of a pharmacy is transferred from one person to another, upon the conditions and for any periods of time as the board determines to be in the public interest. A temporary permit fee shall be established by the board at an amount not to exceed the annual fee for renewal of a permit to

conduct a pharmacy. When needed to protect public safety, a temporary permit may be issued for a period not to exceed 180 days, and may be issued subject to terms and conditions the board deems necessary. If the board determines a temporary permit was issued by mistake or denies the application for a permanent license or registration, the temporary license or registration shall terminate upon either personal service of the notice of termination upon the permit holder or service by certified mail, return receipt requested, at the permit holder's address of record with the board, whichever comes first. Neither for purposes of retaining a temporary permit nor for purposes of any disciplinary or license denial proceeding before the board shall the temporary permit holder be deemed to have a vested property right or interest in the permit.

(c) The board may allow the temporary use of a mobile pharmacy, when a pharmacy is destroyed or damaged and when needed to protect the health and safety of the public and the following conditions are met:

- (1) The mobile pharmacy shall provide services only on or immediately contiguous to the site of the damaged or destroyed pharmacy.
- (2) The mobile pharmacy is under the control and management of the Pharmacist-in-Charge of the pharmacy that was destroyed or damaged.
- (3) A licensed pharmacist is on the premises while drugs are being dispensed.
- (4) Reasonable security measures are taken to safeguard the drug supply maintained in the mobile pharmacy.
- (5) The pharmacy operating the mobile pharmacy provides the board with records of the destruction or damage and an expected restoration date.
- (6) Within three (3) calendar days of restoration of the pharmacy services, the board is provided with notice of the restoration to the permanent pharmacy.
- (7) The mobile pharmacy is not operated for more than forty-eight (48) hours following the restoration of the pharmacy.

§ 4111. Restrictions on Prescriber Ownership

(a) Except as otherwise provided in subdivision (b), (d), or (e), the board shall not issue or renew a license to conduct a pharmacy to any of the following:

- (1) A person or persons authorized to prescribe or write a prescription, as specified in Section 4040, in the State of California.
- (2) A person or persons with whom a person or persons specified in paragraph (1) shares a community or other financial interest in the permit sought.
- (3) Any corporation that is controlled by, or in which 10 percent or more of the stock is owned by a person or persons prohibited from pharmacy ownership by paragraph (1) or (2).

(b) Subdivision (a) shall not preclude the issuance of a permit for an inpatient hospital pharmacy to the owner of the hospital in which it is located.

(c) The board may require any information the board deems is reasonably necessary for the enforcement of this section.

(d) Subdivision (a) shall not preclude the issuance of a new or renewal license for a pharmacy to be owned or owned and operated by a person licensed on or before August 1, 1981, under the Knox-Keene Health Care Service Plan Act of 1975 (Chapter 2.2 (commencing with Section 1340) of Division 2 of the Health and Safety Code) and qualified on or before August 1, 1981, under subsection (d) of Section 1310 of Title XIII of the federal Public Health Service Act, as amended, whose ownership includes persons defined pursuant to paragraphs (1) and (2) of subdivision (a).

(e) Subdivision (a) shall not preclude the issuance of a new or renewal license for a pharmacy to be owned or owned and operated by a pharmacist authorized to issue a drug order pursuant to subparagraph (D) of paragraph (4) of, or clause (iv) of subparagraph (A) of paragraph (5) of, subdivision (a) of Section 4052 ~~4052.2~~.

§ 4113. Pharmacists-in-charge; designation approval; responsibilities; notifications

(a) Every pharmacy shall ~~designate a pharmacist in charge and within 30 days thereof, shall notify the board in writing of the identity and license number of that pharmacist and the date he or she was designated be supervised or managed by a pharmacist-in-charge. As part of its initial application for a license, and for each renewal, each pharmacy shall, on a form designed by the board, provide identifying information and the California license number for a pharmacist proposed to serve as the pharmacist-in-charge. The proposed pharmacist-in-charge shall be subject to approval by the board. The board shall not issue or renew a pharmacy license without identification of an approved pharmacist-in-charge for the pharmacy.~~

(b) The pharmacist-in-charge shall be responsible for a pharmacy's compliance with all state and federal laws and regulations pertaining to the practice of pharmacy.

(c) Every pharmacy shall ~~notify the board in writing, on a form designed by the board, within 30 days of the date when a pharmacist ceases to be a pharmacist-in-charge ceases to act as pharmacist-in-charge, and shall on the same form propose another pharmacist to take over as pharmacist-in-charge. The proposed replacement pharmacist-in-charge shall be subject to approval by the board. If disapproved, the pharmacy shall propose another replacement within 15 days of the date of disapproval, and shall continue to name proposed replacements until a pharmacist-in-charge is approved by the board.~~

(d) ~~If a pharmacy is unable, in the exercise of reasonable diligence, to identify within 30 days a permanent replacement pharmacist-in-charge to propose to the board on the notification form, the pharmacy may instead supply on that form the name of any pharmacist who is an employee, officer or administrator of the pharmacy or the entity which owns the pharmacy and who is actively involved in the management of the pharmacy on a daily basis, to act as the interim pharmacist-in-charge for a period not to exceed 120 days. The pharmacy, or the entity which owns the pharmacy, shall be prepared during normal business hours to provide a representative of the board with the name of the interim pharmacist-in-charge, with documentation of the active involvement of the interim pharmacist-in-charge in the daily management of the pharmacy, and with documentation of the pharmacy's good faith efforts prior to naming the interim pharmacist-in-charge to obtain a permanent pharmacist-in-charge. By no later than 120 days following the identification of the interim pharmacist-in-charge, the pharmacy shall propose to the board the name of a pharmacist to serve as the permanent pharmacist-in-charge. The proposed permanent pharmacist-in-charge shall be subject to approval by the board. If disapproved, the pharmacy shall propose another replacement within 15 days of the date of disapproval, and shall continue to name proposed replacements until a pharmacist-in-charge is approved by the board.~~

§ 4126.5. Persons or organizations that pharmacies may furnish with dangerous drugs; violations; offset of amounts due; definitions

- (a) A pharmacy may furnish dangerous drugs only to the following, and only the following may receive dangerous drugs furnished by a pharmacy:
- (1) A wholesaler owned or under common control by the wholesaler from whom the dangerous drug was acquired.
 - (2) The pharmaceutical manufacturer from whom the dangerous drug was acquired.
 - (3) A licensed wholesaler acting as a reverse distributor.
 - (4) Another pharmacy or wholesaler to alleviate a temporary shortage of a dangerous drug that could result in the denial of health care. A pharmacy furnishing dangerous drugs pursuant to this paragraph may only furnish a quantity sufficient to alleviate the temporary shortage.
 - (5) A patient or to another pharmacy pursuant to a prescription or as otherwise authorized by law.
 - (6) A health care provider that is not a pharmacy but that is authorized to purchase dangerous drugs.
 - (7) To another pharmacy under common control.
- (b) ~~Notwithstanding any other provision of law, a violation of this section by either a pharmacy whose primary or sole business is filling prescriptions for patients of long-term care facilities or a person engaged in a prohibited transaction with a pharmacy whose primary or sole business is filling prescriptions for patients of long-term care facilities may subject the person or persons who committed the violation to a fine not to exceed the amount specified in Section 125.9 for each occurrence pursuant to a citation issued by the board.~~
- (c) Amounts due from any person under this section on or after January 1, 2005, shall be offset as provided under Section 12419.5 of the Government Code. Amounts received by the board under this section shall be deposited into the Pharmacy Board Contingent Fund.
- (d) For purposes of this section, "common control" means the power to direct or cause the direction of the management and policies of another person whether by ownership, by voting rights, by contract, or by other means.

For purposes of subdivision (b) of this section and subdivision (s) of Section 4301, "long-term care facility" shall have the same meaning given the term in Section 1418 of the Health and Safety Code.

§ 4160. Wholesaler Licenses

- (a) A person may not act as a wholesaler of any dangerous drug or dangerous device unless he or she has obtained a license from the board.
- (b) Upon approval by the board and the payment of the required fee, the board shall issue a license to the applicant.

(c) A separate license shall be required for each place of business owned or operated by a wholesaler. Each license shall be renewed annually and shall not be transferable.

~~(d) The board shall not issue or renew a wholesaler license until the wholesaler identifies a designated representative in charge and notifies the board in writing of the identity and license number of that designated representative. Every wholesaler shall be supervised or managed by a designated representative-in-charge. The designated representative-in-charge shall be responsible for the wholesaler's compliance with state and federal laws governing wholesalers. As part of its initial application for a license, and for each renewal, each wholesaler shall, on a form designed by the board, provide identifying information and the California license number for a designated representative or pharmacist proposed to serve as the designated representative-in-charge. The proposed designated representative-in-charge shall be subject to approval by the board. The board shall not issue or renew a wholesaler license without identification of an approved designated representative-in-charge for the wholesaler.~~

~~(e) A wholesaler shall identify and notify the board of a new designated representative in charge within 30 days of the date that the prior designated representative in charge ceases to be the designated representative in charge. A pharmacist may be identified as the designated representative in charge. Every wholesaler shall notify the board in writing, on a form designed by the board, within 30 days of the date when a designated representative-in-charge ceases to act as designated representative-in-charge, and shall on the same form propose another designated representative or pharmacist to take over as designated representative-in-charge. The proposed replacement designated representative-in-charge shall be subject to approval by the board. If disapproved, the wholesaler shall propose another replacement within 15 days of the date of disapproval, and shall continue to name proposed replacements until a designated representative-in-charge is approved by the board.~~

(e f) A drug manufacturer licensed by the Food and Drug Administration or licensed pursuant to Section 111615 of the Health and Safety Code that only distributes dangerous drugs and dangerous devices of its own manufacture is exempt from this section and Section 4161.

~~(f g) The board may issue a temporary license, upon conditions and for periods of time as the board determines to be in the public interest. A temporary license fee shall be five hundred fifty dollars (\$550) six hundred dollars (\$600) or another amount established by the board not to exceed the annual fee for renewal of a license to compound injectable sterile drug products. When needed to protect public safety, a temporary license may be issued for a period not to exceed 180 days, subject to terms and conditions that the board deems necessary. If the board determines that a temporary license was issued by mistake or denies the application for a permanent license, the temporary license shall terminate upon either personal service of the notice of termination upon the licenseholder or service by certified mail, return receipt requested, at the licenseholder's address of record with the board, whichever occurs first. Neither for purposes of retaining a temporary license, nor for purposes of any disciplinary or license denial proceeding before the board, shall the temporary licenseholder be deemed to have a vested property right or interest in the license.~~

~~(g) This section shall become operative on January 1, 2006.~~

§ 4174. Dispensing by Pharmacist Upon Order of a Nurse Practitioner

Notwithstanding any other provision of law, a pharmacist may dispense drugs or devices upon the drug order of a nurse practitioner functioning pursuant to Section 2836.1 or a certified

nurse-midwife functioning pursuant to Section 2746.51, a drug order of a physician assistant functioning pursuant to Section 3502.1 or a naturopathic doctor functioning pursuant to Section 3640.5, or the order of a pharmacist acting under Section 4052 ~~4052.2~~.

§ 4196. Veterinary Food-Animal Drug Retailer Licenses; persons allowed in areas where drugs stored, possessed, or repacked

(a) No person shall conduct a veterinary food-animal drug retailer in the State of California unless he or she has obtained a license from the board. A license shall be required for each veterinary food-animal drug retailer owned or operated by a specific person. A separate license shall be required for each of the premises of any person operating a veterinary food-animal drug retailer in more than one location. The license shall be renewed annually and shall not be transferable.

(b) The board may issue a temporary license, upon conditions and for periods of time as the board determines to be in the public interest. A temporary license fee shall be fixed by the board at an amount not to exceed the annual fee for renewal of a license to conduct a veterinary food-animal drug retailer.

(c) No person other than a pharmacist, an intern pharmacist, a designated representative, an authorized officer of the law, or a person authorized to prescribe, shall be permitted in that area, place, or premises described in the permit issued by the board pursuant to Section 4041, wherein veterinary food-animal drugs are stored, possessed, or repacked. A pharmacist or designated representative shall be responsible for any individual who enters the veterinary food-animal drug retailer for the purpose of performing clerical, inventory control, housekeeping, delivery, maintenance, or similar functions relating to the veterinary food-animal drug retailer.

~~(d) The board shall not issue or renew a veterinary food-animal retailer license until the veterinary food-animal drug retailer identifies a designated representative in charge and notifies the board in writing of the identity and license number of that designated representative. Every veterinary food-animal drug retailer shall be supervised or managed by a designated representative-in-charge. The designated representative-in-charge shall be responsible for the veterinary food-animal drug retailer's compliance with state and federal laws governing veterinary food-animal drug retailers. As part of its initial application for a license, and for each renewal, each veterinary food-animal drug retailer shall, on a form designed by the board, provide identifying information and the California license number for a designated representative or pharmacist proposed to serve as the designated representative-in-charge. The proposed designated representative-in-charge shall be subject to approval by the board. The board shall not issue or renew a veterinary food-animal drug retailer license without identification of an approved designated representative-in-charge for the veterinary food-animal drug retailer.~~

~~(e) Each veterinary food-animal drug retailer shall identify, and notify the board of, a new designated representative in charge within 30 days of the date that the prior designated representative in charge ceases to be the designated representative in charge. A pharmacist may be identified as the designated representative in charge. Every veterinary food-animal drug retailer shall notify the board in writing, on a form designed by the board, within 30 days of the date when a designated representative-in-charge who ceases to act as designated representative-in-charge, and shall on the same form propose another designated representative or pharmacist to take over as designated representative-in-charge. The proposed replacement designated representative-in-charge shall be subject to approval by the~~

board. If disapproved, the veterinary food-animal drug retailer shall propose another replacement within 15 days of the date of disapproval, and shall continue to name proposed replacements until a designated representative-in-charge is approved by the board.

(e f) For purposes of this section, designated representative-in-charge means a person granted a designated representative license pursuant to Section 4053, or a registered pharmacist, who is the supervisor or manager of the facility.

~~(f) This section shall become operative on January 1, 2006.~~

§ 4231. Requirements for renewal of pharmacist license; clock hours; exemption for new licensee

(a) The board shall not renew a pharmacist license unless the applicant submits proof satisfactory to the board that he or she has successfully completed 30 hours of approved courses of continuing pharmacy education during the two years preceding the application for renewal.

(b) Notwithstanding subdivision (a), the board shall not require completion of continuing education for the first renewal of a pharmacist license.

(c) If an applicant for renewal of a pharmacist license submits the renewal application and payment of the renewal fee but does not submit proof satisfactory to the board that the licensee has completed 30 hours of continuing pharmacy education, the board shall not renew the license and shall issue the applicant an inactive pharmacist license. A licensee with an inactive pharmacist license issued pursuant to this section may obtain an active pharmacist license by paying the renewal fees due and submitting satisfactory proof to the board that the licensee has completed 30 hours of continuing pharmacy education.

(d) If, as part of an investigation or audit conducted by the board, a pharmacist fails to provide documentation substantiating the completion of continuing education as required in subdivision (a) the board shall cancel the active pharmacist license and issue an inactive pharmacist license in its place. A licensee with an inactive pharmacist license issued pursuant to this section may obtain an active pharmacist license by paying the renewal fees due and submitting satisfactory proof to the board that the licensee has completed 30 hours of continuing pharmacy education.

§ 4305. Licensees conducting pharmacies; Pharmacist-in-charge; notice to board; disciplinary action

~~(a) Any person who has obtained a license to conduct a pharmacy, shall notify the board within 30 days of the termination of employment of any pharmacist who takes charge of, or acts as manager of the pharmacy. Failure by any pharmacist to notify the board in writing that he or she has ceased to act as pharmacist-in-charge of a pharmacy, or by any pharmacy to notify the board in writing that a pharmacist-in-charge is no longer acting in that capacity, within the 30-day period specified by sections 4101 and 4113, shall constitute grounds for disciplinary action.~~

(b) Operation of a pharmacy for more than 30 days without supervision or management thereof by a pharmacist-in-charge shall constitute grounds for disciplinary action.

~~(b c)~~ Any person who has obtained a license to conduct a pharmacy, who willfully fails to timely notify the board of the termination of employment of that any pharmacist who takes charge of, or acts as manager the pharmacist-in-charge of the pharmacy has ceased to act in that capacity, and who continues to permit the compounding or dispensing of prescriptions, or the furnishing of drugs or poisons, in his or her pharmacy, except by a pharmacist subject to the supervision and management of a responsible pharmacist-in-charge, shall be subject to summary suspension or revocation of his or her license to conduct a pharmacy.

~~(c) Any pharmacist who takes charge of, or acts as manager of a pharmacy, who terminates his or her employment at the pharmacy, shall notify the board within 30 days of termination of employment. Failure to notify the board within the 30-day period shall constitute grounds for disciplinary action.~~

§ 4329. Nonpharmacists; prohibited acts

Any nonpharmacist who takes charge of or acts as supervisor, manager, or pharmacist-in-charge of any pharmacy, or who compounds or dispenses a prescription or furnishes dangerous drugs except as otherwise provided in this chapter, is guilty of a misdemeanor.

§ 4330. Proprietors; prohibited acts

(a) Any person who has obtained a license to conduct a pharmacy, who fails to place in charge of the pharmacy a pharmacist, or any person, who by himself or herself, or by any other person, permits the compounding or dispensing of prescriptions, or the furnishing of dangerous drugs, in his or her pharmacy, except by a pharmacist, or as otherwise provided in this chapter, is guilty of a misdemeanor.

(b) Any ~~nonpharmacist~~ pharmacy owner who commits any act that would subvert or tend to subvert the efforts of the pharmacist-in-charge to comply with the laws governing the operation of the pharmacy is guilty of a misdemeanor.

§ 4362. Entry into the Pharmacists Recovery Program

(a) A pharmacist or intern pharmacist may enter the pharmacists recovery program if:

- (1) The pharmacist or intern pharmacist is referred by the board instead of, or in addition to, other means of disciplinary action.
- (2) The pharmacist or intern pharmacist voluntarily elects to enter the pharmacists recovery program.

(b) A pharmacist or intern pharmacist who enters the pharmacists recovery program pursuant to paragraph (2) of subdivision (a) shall not be subject to discipline or other enforcement action by the board solely on his or her entry into the pharmacists recovery program or on information obtained from the pharmacist or intern pharmacist while participating in the program unless the pharmacist or intern pharmacist would pose a threat to the health and safety of the public. However, if the board receives information regarding the conduct of the pharmacist or intern pharmacist, that information may serve as a basis for discipline or other enforcement by the board.

(c) A pharmacist or intern pharmacist enrolled in the pharmacists recovery program shall be responsible to pay an administrative co-pay of \$125 monthly to cover a portion of the administrative costs borne by the board to contract for these services. This fee may be waived, reduced, or deferred by the board or its designee if the participant demonstrates a financial hardship.

Health and Safety Code Amendment

§ 11150 – Persons Authorized to Write or Issue a Prescription

No person other than a physician, dentist, podiatrist, or veterinarian, or pharmacist acting within the scope of a project authorized under Article 1 (commencing with Section 128125) of Chapter 3 of Part 3 of Division 107 or within the scope of either subparagraph (D) of paragraph (4) of, or clause (iv) of subparagraph (A) of paragraph (5) of, subdivision (a) of Section 4052.2 of the Business and Professions Code, a registered nurse acting within the scope of a project authorized under Article 1 (commencing with Section 128125) of Chapter 3 of Part 3 of Division 107, a certified nurse-midwife acting within the scope of Section 2746.51 of the Business and Professions Code, a nurse practitioner acting within the scope of Section 2836.1 of the Business and Professions Code, a physician assistant acting within the scope of a project authorized under Article 1 (commencing with Section 128125) of Chapter 3 of Part 3 of Division 107 or Section 3502.1 of the Business and Professions Code, or an optometrist acting within the scope of Section 3041 of the Business and Professions Code, or an out-of-state prescriber acting pursuant to Section 4005 of the Business and Professions Code shall write or issue a prescription.

§ 11165. Controlled Substance Utilization Review and Evaluation System: Establishment; Operations; Funding; Reporting to Legislature

(a) To assist law enforcement and regulatory agencies in their efforts to control the diversion and resultant abuse of Schedule II, Schedule III, and Schedule IV controlled substances, and for statistical analysis, education, and research, the Department of Justice shall, contingent upon the availability of adequate funds from the Contingent Fund of the Medical Board of California, the Pharmacy Board Contingent Fund, the State Dentistry Fund, the Board of Registered Nursing Fund, and the Osteopathic Medical Board of California Contingent Fund, maintain the Controlled Substance Utilization Review and Evaluation System (CURES) for the electronic monitoring of the prescribing and dispensing of Schedule II, Schedule III, and Schedule IV controlled substances by all practitioners authorized to prescribe or dispense these controlled substances.

(b) The reporting of Schedule III and Schedule IV controlled substance prescriptions to CURES shall be contingent upon the availability of adequate funds from the Department of Justice. The Department of Justice may seek and use grant funds to pay the costs incurred from the reporting of controlled substance prescriptions to CURES. Funds shall not be appropriated from the Contingent Fund of the Medical Board of California, the Pharmacy Board Contingent Fund, the State Dentistry Fund, the Board of Registered Nursing Fund, the Naturopathic Doctor's Fund, or the Osteopathic Medical Board of California Contingent Fund to pay the costs of reporting Schedule III and Schedule IV controlled substance prescriptions to CURES.

(c) CURES shall operate under existing provisions of law to safeguard the privacy and confidentiality of patients. Data obtained from CURES shall only be provided to appropriate

state, local, and federal persons or public agencies for disciplinary, civil, or criminal purposes and to other agencies or entities, as determined by the Department of Justice, for the purpose of educating practitioners and others in lieu of disciplinary, civil, or criminal actions. Data may be provided to public or private entities, as approved by the Department of Justice, for educational, peer review, statistical, or research purposes, provided that patient information, including any information that may identify the patient, is not compromised. Further, data disclosed to any individual or agency as described in this subdivision shall not be disclosed, sold, or transferred to any third party.

(d) For each prescription for a Schedule II, Schedule III, or Schedule IV controlled substance, the dispensing pharmacy or clinic shall provide the following information to the Department of Justice on a weekly basis and in a format specified by the Department of Justice:

- (1) Full name, address, and the telephone number of the ultimate user or research subject, or contact information as determined by the Secretary of the United States Department of Health and Human Services, and the gender, and date of birth of the ultimate user.
- (2) The prescriber's category of licensure and license number; federal controlled substance registration number; and the state medical license number of any prescriber using the federal controlled substance registration number of a government-exempt facility.
- (3) Pharmacy prescription number, license number, and federal controlled substance registration number.
- (4) NDC (National Drug Code) number of the controlled substance dispensed.
- (5) Quantity of the controlled substance dispensed.
- (6) ICD-9 (diagnosis code), if available.
- (7) Number of refills ordered.
- (8) Whether the drug was dispensed as a refill of a prescription or as a first-time request.
- (9) Date of origin of the prescription.
- (10) Date of dispensing of the prescription.

(e) This section shall become operative on January 1, 2005.